Horizon Discovery Group plc Capital Markets Day Date Change to 5 March 2018 (3297F)
20 February 2018 - 6:01PM
UK Regulatory
TIDMHZD
RNS Number : 3297F
Horizon Discovery Group plc
20 February 2018
Horizon Discovery Group plc
Capital Markets Day Date Change to 5 March 2018
Cambridge, UK, 20 February 2018: Horizon Discovery Group plc
(LSE: HZD) ("Horizon" or "the Group"), a global leader in gene
editing and gene modulation technologies, announces that as a
result of the leadership changes announced separately today, the
Capital Markets Day in London for investors and sell-side analysts,
will now take place on 5 March 2018 at Etc. Venues Fenchurch
Street, 43/44 Crutched Friars, London, EC3N 2HH starting at 13:00
GMT / 8:00 EDT.
There will be a simultaneous live conference call and webcast
for those unable to attend in person. The webcast, with the
presentation slides, will be available at
https://www.horizondiscovery.com/about-us/investor-relations and a
recording will be made available shortly thereafter.
Please contact horizon@consilium-comms.com if you would like to
attend.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Ian Gilham, Chairman
Richard Vellacott, Interim Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the tic
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDDGDDRXBBGIC
(END) Dow Jones Newswires
February 20, 2018 02:01 ET (07:01 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024